Eagle's Eye View: Your Weekly CV Update From ACC.org podkast

Key Takeaways from ACC.25 Major Trials and Presentations

0:00
9:25
Do tyłu o 15 sekund
Do przodu o 15 sekund

In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including:  

  • Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up  

  • SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI) 

  • DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI) 

  • STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes 

  • RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus  

  • API-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE) 

 

Subscribe to Eagle’s Eye View  

Więcej odcinków z kanału "Eagle's Eye View: Your Weekly CV Update From ACC.org"